Your browser is no longer supported. Please, upgrade your browser.
Settings
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-6.79 Insider Own0.20% Shs Outstand65.79M Perf Week6.93%
Market Cap13.67B Forward P/E6.34 EPS next Y32.84 Insider Trans-55.90% Shs Float62.53M Perf Month-8.81%
Income-418.30M PEG- EPS next Q-2.65 Inst Own53.20% Short Float6.87% Perf Quarter62.62%
Sales475.60M P/S28.73 EPS this Y-32.00% Inst Trans25.88% Short Ratio0.99 Perf Half Y94.46%
Book/sh9.53 P/B21.84 EPS next Y65.68% ROA-44.20% Target Price300.75 Perf Year774.58%
Cash/sh10.83 P/C19.22 EPS next 5Y0.00% ROE-187.10% 52W Range16.41 - 331.68 Perf YTD86.66%
Dividend- P/FCF- EPS past 5Y9.50% ROI-38.00% 52W High-37.97% Beta1.46
Dividend %- Quick Ratio2.20 Sales past 5Y67.30% Gross Margin- 52W Low1153.78% ATR17.53
Employees791 Current Ratio2.20 Sales Q/Q3072.20% Oper. Margin-87.60% RSI (14)52.74 Volatility9.17% 8.93%
OptionableYes Debt/Eq0.75 EPS Q/Q-138.40% Profit Margin-87.90% Rel Volume1.36 Prev Close208.15
ShortableYes LT Debt/Eq0.58 EarningsMar 01 AMC Payout- Avg Volume4.33M Price205.74
Recom2.00 SMA208.03% SMA50-4.69% SMA20041.44% Volume626,052 Change-1.16%
Dec-14-20Initiated Jefferies Buy $200
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18Upgrade JP Morgan Underweight → Overweight
Mar-29-18Upgrade Seaport Global Securities Neutral → Buy $5
Apr-21-21 07:00AM  
06:01AM  
Apr-20-21 02:15PM  
10:49AM  
10:22AM  
09:35AM  
Apr-19-21 01:49PM  
06:00AM  
Apr-17-21 09:26AM  
08:23AM  
Apr-16-21 02:57PM  
01:53PM  
09:23AM  
09:22AM  
06:30AM  
Apr-15-21 05:45PM  
04:43PM  
03:13PM  
02:04PM  
09:20AM  
07:49AM  
06:09AM  
Apr-14-21 05:39PM  
02:46PM  
02:11PM  
01:43PM  
12:23PM  
11:02AM  
09:34AM  
09:13AM  
06:31AM  
06:01AM  
05:35AM  
Apr-13-21 07:01PM  
05:52PM  
05:34PM  
02:09PM  
11:00AM  
09:28AM  
06:00AM  
Apr-12-21 01:51PM  
Apr-11-21 06:04AM  
Apr-10-21 09:03AM  
06:30AM  
05:56AM  
Apr-09-21 10:59PM  
05:45PM  
01:39PM  
06:06AM  
Apr-08-21 05:00PM  
03:23PM  
01:23PM  
08:05AM  
Apr-07-21 05:12PM  
01:26PM  
11:01AM  
09:36AM  
07:00AM  
Apr-06-21 02:43PM  
01:29PM  
11:09AM  
08:04AM  
07:29AM  
Apr-05-21 05:59PM  
04:59PM  
04:31PM  
04:05PM  
04:05PM  
02:06PM  
01:58PM  
01:23PM  
11:40AM  
08:50AM  
08:32AM  
05:37AM  
02:05AM  
Apr-03-21 06:10AM  
Apr-01-21 02:46PM  
02:07PM  
01:46PM  
10:33AM  
08:58AM  
Mar-31-21 01:42PM  
06:04AM  
06:00AM  
Mar-30-21 05:45PM  
03:15PM  
01:44PM  
01:27PM  
10:44AM  
10:40AM  
Mar-29-21 08:55PM  
08:48PM  
04:20PM  
04:02PM  
02:40PM  
02:10PM  
02:05PM  
12:53PM  
12:00PM  
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trizzino JohnEVP, Chief Commercial OfficerApr 07Sale178.0319134,004287Apr 07 05:09 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 05Option Exercise34.013,404115,7713,308Apr 07 05:09 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 05Sale190.103,021574,292287Apr 07 05:09 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 26Option Exercise14.822,89442,8863,169Mar 30 06:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 26Sale186.802,894540,609275Mar 30 06:10 PM
YOUNG JAMES FDirectorMar 25Option Exercise8.9647,500425,43857,500Mar 25 06:41 PM
YOUNG JAMES FDirectorMar 23Option Exercise46.0010,000460,00020,000Mar 25 06:41 PM
YOUNG JAMES FDirectorMar 23Sale228.2210,0002,282,23110,000Mar 25 06:41 PM
MCMANUS MICHAEL A JRDirectorMar 19Sale220.784,000883,1105,951Mar 23 05:33 PM
Glenn Gregory MPresident, R&DMar 17Sale218.862,423530,3042,811Mar 17 06:35 PM
Glenn Gregory MPresident, R&DMar 15Option Exercise109.9510,5311,157,8438,523Mar 17 06:35 PM
EVANS GARY CDirectorMar 15Option Exercise19.5224,500478,33040,599Mar 17 06:36 PM
EVANS GARY CDirectorMar 15Sale211.2124,5005,174,53616,099Mar 17 06:36 PM
Glenn Gregory MPresident, R&DMar 15Sale198.605,7121,134,4002,811Mar 17 06:35 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 09Sale168.0919031,937287Mar 09 07:38 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 05Option Exercise14.733,40450,1483,308Mar 09 07:38 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 05Sale163.463,021493,824287Mar 09 07:38 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Option Exercise14.822,89542,8923,170Mar 02 05:37 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Sale225.482,895652,759275Mar 02 05:37 PM
Glenn Gregory MPresident, R&DFeb 18Sale269.572,434656,1342,811Feb 18 06:59 PM
Glenn Gregory MPresident, R&DFeb 16Option Exercise13.1610,531138,5778,523Feb 18 06:55 PM
Glenn Gregory MPresident, R&DFeb 16Sale282.715,7121,614,8122,811Feb 18 06:55 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 09Sale324.5019462,953287Feb 09 07:40 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 05Option Exercise14.733,40650,1603,309Feb 09 07:40 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 05Sale290.463,022877,766287Feb 09 07:40 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 01Option Exercise18.1515,022272,72415,297Feb 03 05:37 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 01Sale241.5015,0223,627,789275Feb 03 05:37 PM
Trizzino JohnEVP, CMO and CBOJan 07Sale124.1750662,830287Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Option Exercise18.6313,756256,24317,694Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Sale112.0017,4071,949,522287Jan 07 07:08 PM
YOUNG JAMES FDirectorDec 31Option Exercise51.2711,000564,00011,000Jan 05 05:38 PM
DOUGLAS RICHARDDirectorDec 31Option Exercise50.001,00050,00028,500Jan 05 05:42 PM
YOUNG JAMES FDirectorDec 31Sale113.0911,0001,244,0140Jan 05 05:38 PM
Erck Stanley CPresident and CEONov 16Option Exercise37.1452,3171,942,80172,811Nov 18 06:09 PM
Erck Stanley CPresident and CEONov 16Sale90.6552,3164,742,66720,495Nov 18 06:09 PM
Erck Stanley CPresident and CEOOct 01Sale108.56221720,494Oct 01 05:39 PM
Trizzino JohnEVP, CBO and CFOSep 30Sale110.222,250248,0025,087Oct 01 05:40 PM
Erck Stanley CPresident and CEOSep 30Sale110.2312,2311,348,20020,496Oct 01 05:39 PM
Erck Stanley CPresident and CEOSep 29Sale107.804,112443,26732,727Sep 30 09:27 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 29Sale107.3118,0291,934,667275Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 29Sale107.0219,9492,134,8441,561Sep 30 09:29 PM
Trizzino JohnEVP, CBO and CFOSep 29Sale107.2918,3211,965,6307,337Sep 30 09:28 PM
Trizzino JohnEVP, CBO and CFOSep 28Option Exercise5.9529,600176,12053,008Sep 30 09:28 PM
Erck Stanley CPresident and CEOSep 28Option Exercise5.9550,000297,50074,606Sep 30 09:27 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Option Exercise5.9524,750147,26243,054Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 28Option Exercise5.9525,000148,75046,510Sep 30 09:29 PM
Erck Stanley CPresident and CEOSep 28Sale110.3025,0002,757,45636,839Sep 30 09:27 PM
Glenn Gregory MPresident, R&DSep 28Sale110.3025,0002,757,45621,510Sep 30 09:29 PM
Trizzino JohnEVP, CBO and CFOSep 28Sale110.3025,0002,757,45625,658Sep 30 09:28 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Sale110.3024,7502,729,87918,304Sep 30 09:30 PM
EVANS GARY CDirectorAug 18Option Exercise31.0210,500325,700332,479Aug 20 06:09 PM
Glenn Gregory MPresident, R&DAug 18Option Exercise33.5655,9211,876,52557,760Aug 20 06:14 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Option Exercise53.8246,2422,488,61346,517Aug 20 06:20 PM
MCMANUS MICHAEL A JRDirectorAug 18Option Exercise27.608,000220,80017,951Aug 20 06:22 PM
Trizzino JohnEVP, CBO and CFOAug 18Option Exercise50.9542,7882,179,98647,875Aug 20 06:25 PM
Trizzino JohnEVP, CBO and CFOAug 18Sale148.7842,7886,366,1825,087Aug 20 06:25 PM
MCMANUS MICHAEL A JRDirectorAug 18Sale146.008,0001,168,0009,951Aug 20 06:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Sale144.3346,2426,673,982275Aug 20 06:20 PM
Glenn Gregory MPresident, R&DAug 18Sale145.2055,9218,119,8601,839Aug 20 06:14 PM
EVANS GARY CDirectorAug 18Sale150.4410,5001,579,620321,979Aug 20 06:09 PM
Glenn Gregory MPresident, R&DJun 18Option Exercise42.2016,749706,80818,588Jun 22 05:29 PM
Glenn Gregory MPresident, R&DJun 18Sale59.5316,749997,1031,839Jun 22 05:29 PM
YOUNG JAMES FDirectorJun 03Buy48.831,50073,2451,500Jun 05 05:04 PM
Herrmann John A IIISVP, General CounselMay 18Option Exercise26.1912,961339,4487,774May 20 04:35 PM
Herrmann John A IIISVP, General CounselMay 18Sale49.4412,961640,792275May 20 04:35 PM